Benitec Biopharma prices $100M equity offering at $13.50/share (7.4M shares total)

Benitec Biopharma Inc.

Underwritten public offering of 5,930,000 shares plus 889,500-share underwriter option; concurrent registered direct offering of 1,481,481 shares to Suvretta Capital affiliates.
Gross proceeds ~$100M; net proceeds to fund product candidate programs, working capital, and general corporate purposes.
Offerings priced at $13.50 per share; expected to close Nov 7, 2025 subject to customary conditions.
Company, execs, directors, and Suvretta Capital subject to 90-day lock-up on share sales after Nov 5, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.